Immunotherapy of Bronchogenic Carcinoma and Its Perspectives

Czech version

Authors: L. Koubková
Authors‘ workplace: Pneumologická klinika 2. LF UK a FN v Motole, Praha
Published in: Klin Onkol 2015; 28(Supplementum 4): 77-81
Category: Specials
doi: https://doi.org/10.14735/amko20154S77

Overview

Immunotherapy is becoming another possible alternative in the treatment of lung cancer. It is a completely different method of treating cancer which is not directed to the tumor itself, but to the immune system. Surface antigens present on tumor cells may be an effective and specific therapeutic targets and strategies based on antibodies inhibiting immune check-points significantly improves the anti‑tumor immune response. Monoclonal antibody blocking CTLA‑ 4 (cytotoxic T-lymphocyte antigen) and PD‑ 1 receptor (protein programmed cell death) and its ligand PD‑ L1 showed clinical efficacy and nivolumab (anti‑PD‑ 1) was approved in 2^nd line treatment squamous non‑small cell lung cancer.

Key words:
bronchogenic carcinoma – vaccines – immune checkpoints

The author declares she has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
27. 7. 2015

Accepted:
23. 10. 2015

Sources

1. Ferlay J, Soerjomataram I, Ervik M et al (eds). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [monograph on the Internet]. Lyon: International Agency for Research on Cancer. Available from: http:/ / globocan.iarc.fr.

2. Vansteenkiste J, Zielinski M, Linder A et al. Adjuvant MAGE‑ A3 immunotherapy in resected non‑small‑cell lung cancer: phase II randomized study results. J Clin Oncol 2013; 31(19): 2396– 2403. doi: 10.1200/ JCO.2012.43.7103.

3. Butts CA, Socinski MA, Mitchell P et al. START: a phase IIIstudy of L‑ BLP25 cancer immunotherapy for unresectable stage III non‑small cell lung cancer. J Clin Oncol 2013; 31 (Suppl): abstr. 7500.

4. Spigel DR, Reckamp KL, Rizvi NA et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti‑programmed death‑ 1 [PD‑ 1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non‑small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (Suppl): abstr. 8009.

5. Paz‑ Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non‑squamous cell (non‑SQ) non‑small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (Suppl): abstr. LBA109.

6. Gettinger SN, Hellmann MD, Shepherd FA et al. First‑line monotherapy with nivolumab (NIVO; anti‑programmed death‑ 1[PD‑ 1]) in advanced non‑small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD‑ 1 ligand (PD‑ L1) expression. J Clin Oncol 2015; 33 (Suppl): abstr. 8025.

7. Antonia SJ, Bendell JC, Tailor MH et al. Phase I/ II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209- 032. J Clin Oncol 2015; 33 (Suppl): abstr. 7503.

8. Garon EB, Rizvi NA, Hui R et al. KEYNOTE‑ 001 Investigators. Pembrolizumab for the treatment of non‑small‑cell lung cancer. N Engl J Med 2015; 372(21): 2018– 2028. doi: 10.1056/ NEJMoa1501824.

9. Spira AI, Park K, Mazières J et al. Efficacy, safety and predictive biomarker results from a randomized phase IIstudy comparing MPDL3280A vs docetaxel in 2L/ 3L NSCLC (POPLAR). J Clin Oncol 2015; 33 (Suppl): abstr. 8010.